Patients with previously treated metastatic pancreatic cancer lived roughly twice as long when given an experimental daily pill called daraxonrasib compared with standard chemotherapy, according to results from a Phase 3 trial of approximately 500 people. The study, known as RASolute 302, was published in The New England Journal of Medicine and presented at the American Society of Clinical Oncology annual meeting. The U.S. Food and Drug Administration has already cleared an expanded-access protocol for the drug, opening a path for eligible patients outside the trial to receive it while regulatory review continues.
Why doubled survival in pancreatic cancer changes the treatment calculus
Pancreatic ductal adenocarcinoma kills most patients within a year of diagnosis, and options after first-line chemotherapy fails have historically added only weeks of life. Against that backdrop, a drug that nearly doubles overall survival in a randomized, controlled setting represents a sharp departure from incremental gains. The RASolute 302 trial enrolled patients with previously treated metastatic disease and randomized them to daraxonrasib or investigator’s choice chemotherapy, with co-primary endpoints of overall survival and progression-free survival.
The practical question now is how quickly the drug reaches patients who need it. The FDA’s decision to permit expanded access before formal approval signals that regulators judged the protocol safe enough to proceed beyond the controlled trial environment. If the survival benefit holds up in real-world use, oncologists treating KRAS-mutant pancreatic cancer patients will face immediate pressure to seek expanded-access enrollment for those who have exhausted standard regimens. Pharmacy claims data over the next 12 months after any FDA clearance could reveal whether KRAS G12-mutant patients disproportionately drive uptake, a pattern that would confirm the drug’s targeted mechanism is guiding prescribing decisions in practice.
RASolute 302 trial data and the institutions behind it
The core evidence comes from a global, randomized, open-label Phase 3 study registered under the identifier NCT06625320. Approximately 500 patients were enrolled and assigned to receive either daraxonrasib, also known by its development code RMC-6236, or chemotherapy selected by their treating physician. The trial’s design, eligibility criteria, and endpoints are documented in the federal registry for the RASolute 302 study, and the primary results were also described in a peer-reviewed article.
The main efficacy and safety findings were detailed in a report in the New England Journal of Medicine, which emphasized that patients receiving daraxonrasib experienced a marked improvement in both overall survival and the time until disease progression compared with those on physician-selected chemotherapy. Median survival in the investigational arm was nearly twice that of the control arm, and progression-free survival followed a similar pattern, suggesting that the benefit was not limited to a small subset of outliers but reflected a broader shift in outcomes.
Academic cancer centers, including UCLA, contributed heavily to enrollment and follow-up. Investigators there characterized daraxonrasib as an investigational daily pill that doubles survival in metastatic pancreatic cancer, underscoring the significance of the findings for a disease where most late-stage trials have failed to move survival curves. Multinational participation also helps support the generalizability of the results across different health systems and patient demographics, though detailed regional analyses have not yet been fully reported.
Daraxonrasib targets the RAS signaling pathway, a molecular driver mutated in the vast majority of pancreatic cancers. KRAS mutations, particularly those affecting codon 12, have long been considered difficult to drug because the protein’s surface offers few obvious binding pockets and because tumors can rapidly develop resistance. The RASolute 302 results represent one of the first times a targeted agent aimed at this pathway has demonstrated a clear overall survival advantage in a late-stage pancreatic cancer trial. A commentary in Nature Reviews Gastroenterology and Hepatology noted that the magnitude of the overall survival difference stands out against typical outcomes in metastatic pancreatic ductal adenocarcinoma, where second-line therapies have historically struggled to extend life by more than a few months.
The FDA’s expanded-access announcement adds a regulatory dimension that goes beyond the trial itself. By determining the expanded-access protocol safe to proceed, the agency created a formal channel for patients who do not qualify for or cannot access the randomized study. This step is not equivalent to approval, but it does allow treating oncologists to request the drug for individual patients with serious or life-threatening conditions who lack comparable alternatives. Sponsors must still collect safety information, but the primary goal of expanded access is treatment rather than research.
Gaps in the evidence and what patients should watch for next
Several questions remain open despite the headline survival result. The published data so far are limited relative to what regulators and clinicians will eventually review, and complete per-protocol analyses, mutation-stratified survival curves, and detailed adverse-event frequencies have not yet been made fully public. Without granular subgroup data, it is not yet clear whether the survival benefit is concentrated in patients with specific KRAS mutations or whether it extends broadly across the pancreatic cancer population enrolled in the trial.
Long-term safety data also remain under review. The open-label design of RASolute 302 means that neither patients nor physicians were blinded to treatment assignment, which can influence reporting of side effects and subjective quality-of-life measures. While independent data-monitoring committees oversee such trials, their minutes and full case-report forms have not been released publicly, limiting the ability of outside researchers to audit the findings in detail or to identify rare toxicities that may emerge with longer follow-up.
Another uncertainty is how daraxonrasib will interact with other components of modern pancreatic cancer care. The trial focused on patients who had already received standard chemotherapy, but real-world practice may involve earlier use of targeted agents, combination regimens, or sequencing strategies that were not tested in RASolute 302. Whether the drug maintains its benefit if given sooner, or in combination with other therapies, will require additional studies.
The expanded-access pathway, while significant, does not yet come with aggregate real-world outcome numbers. Patients and oncologists considering this route should understand that expanded access provides the drug before approval but does not guarantee the same level of monitoring or data collection as a randomized trial. Participation may involve extra clinic visits and laboratory tests, and access can depend on institutional resources and the sponsor’s capacity to supply drug outside formal studies.
The next milestones to watch include the full publication of subgroup and safety data, any FDA advisory committee meeting related to a formal approval application, and early signals from expanded-access registries that could confirm or complicate the trial’s findings. If regulators ultimately grant approval, payers will then face decisions about coverage criteria, potentially tying reimbursement to specific mutation profiles or prior lines of therapy.
For patients with previously treated metastatic pancreatic cancer, the immediate implication is that a new, biologically targeted option may be available through clinical trials or expanded access, even before formal approval. Those interested in daraxonrasib can discuss with their oncologists whether they meet eligibility criteria for ongoing studies or expanded-access programs, and what is known-and still unknown-about the balance of benefits and risks. As more detailed data emerge, the hope is that a once-elusive target in KRAS-driven tumors will translate into a durable, widely accessible advance for one of oncology’s deadliest cancers.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
